糖尿病相关微血管疾病女性的不良妊娠结局及妊娠期疾病进展风险:系统综述与Meta分析
该系统综述与Meta分析纳入56项队列研究、共12,819名糖尿病孕妇,评估糖尿病肾病或视网膜病变对不良妊娠结局及微血管病进展的影响。结果显示糖尿病肾病孕妇发生子痫前期、早产、剖宫产及围产儿不良结局的风险升高,视网膜病变与早产和子痫前期相关,且部分因素与视网膜病变发生或恶化风险升高相关。
要点
- 糖尿病肾病孕妇子痫前期风险OR 10.76(95%CI 6.43至17.99,p<0.001)。
- 糖尿病肾病孕妇围产儿死亡风险OR 2.26(95%CI 1.07至4.75,p=0.032)。
- 视网膜病变与早产(OR 1.67)及子痫前期(OR 2.20)风险升高相关。
核心结论
- 在糖尿病孕妇中,肾病和/或视网膜病变的存在似乎进一步增加孕产妇并发症的风险。
研究设计与样本
- 系统综述与Meta分析,采用前瞻性方案(PROSPERO CRD42017076647)。
- 检索主要数据库(1990年1月至2021年7月)的相关队列研究。
- 纳入56项队列研究,涉及12,819名糖尿病孕妇,其中40项来自欧洲、9项来自北美。
- 使用纽卡斯尔-渥太华量表评估研究质量,采用随机效应Meta分析汇总为比值比(OR)及95%置信区间(CI)。
主要发现
- 与无肾病者相比,糖尿病肾病孕妇子痫前期风险OR 10.76(95%CI 6.43至17.99,p<0.001),早于34周早产风险OR 6.90(95%CI 3.38至14.06,p<0.001),任何早产风险OR 4.48(95%CI 3.40至5.92,p<0.001),剖宫产风险OR 3.04(95%CI 1.24至7.47,p=0.015)。
- 与无肾病者相比,糖尿病肾病孕妇的围产儿死亡风险OR 2.26(95%CI 1.07至4.75,p=0.032),先天异常风险OR 2.71(95%CI 1.58至4.66,p<0.001),小于胎龄儿风险OR 16.89(95%CI 7.07至40.37,p<0.001),新生儿病房入住风险OR 2.59(95%CI 1.72至3.90,p<0.001)。
- 糖尿病视网膜病变与任何早产(OR 1.67,95%CI 1.27至2.20,p<0.001)及子痫前期(OR 2.20,95%CI 1.57至3.10,p<0.001)相关,但与其它并发症无显著关联。
- 与无相应风险因素者相比,视网膜病变发生或恶化的风险在未产妇女(OR 1.75,95%CI 1.28至2.40,p<0.001)、吸烟者(OR 2.31,95%CI 1.25至4.27,p=0.008)、已有增殖性疾病者(OR 2.12,95%CI 1.11至4.04,p=0.022)及糖尿病病程较长者(加权均数差4.51年,95%CI 2.26至6.76,p<0.001)中升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 视网膜病变和肾病定义的异质性。
- 纳入人群同时包括1型和2型糖尿病女性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rise in the global prevalence of diabetes, particularly among younger people, has led to an increase in the number of pregnant women with preexisting diabetes, many of whom have diabetes-related microvascular complications. We aimed to estimate the magnitude of the risks of adverse pregnancy outcomes or disease progression in this population. METHODS AND FINDINGS: We undertook a systematic review and meta-analysis on maternal and perinatal complications in women with type 1 or 2 diabetic microvascular disease and the risk factors for worsening of microvascular disease in pregnancy using a prospective protocol (PROSPERO CRD42017076647). We searched major databases (January 1990 to July 2021) for relevant cohort studies. Study quality was assessed using the Newcastle-Ottawa Scale. We summarized the findings as odds ratios (ORs) with 95% confidence intervals (CIs) using random effects meta-analysis. We included 56 cohort studies involving 12,819 pregnant women with diabetes; including 40 from Europe and 9 from North America. Pregnant women with diabetic nephropathy were at greater risk of preeclampsia (OR 10.76, CI 6.43 to 17.99, p < 0.001), early (<34 weeks) (OR 6.90, 95% CI 3.38 to 14.06, p < 0.001) and any preterm birth (OR 4.48, CI 3.40 to 5.92, p < 0.001), and cesarean section (OR 3.04, CI 1.24 to 7.47, p = 0.015); their babies were at higher risk of perinatal death (OR 2.26, CI 1.07 to 4.75, p = 0.032), congenital abnormality (OR 2.71, CI 1.58 to 4.66, p < 0.001), small for gestational age (OR 16.89, CI 7.07 to 40.37, p < 0.001), and admission to neonatal unit (OR 2.59, CI 1.72 to 3.90, p < 0.001) compared to those without nephropathy. Diabetic retinopathy was associated with any preterm birth (OR 1.67, CI 1.27 to 2.20, p < 0.001) and preeclampsia (OR 2.20, CI 1.57 to 3.10, p < 0.001) but not other complications. The risks of onset or worsening of retinopathy were increased in women who were nulliparous (OR 1.75, 95% CI 1.28 to 2.40, p < 0.001), smokers (OR 2.31, 95% CI 1.25 to 4.27, p = 0.008), with existing proliferative disease (OR 2.12, 95% CI 1.11 to 4.04, p = 0.022), and longer duration of diabetes (weighted mean difference: 4.51 years, 95% CI 2.26 to 6.76, p < 0.001) compared to those without the risk factors. The main limitations of this analysis are the heterogeneity of definition of retinopathy and nephropathy and the inclusion of women both with type 1 and type 2 diabetes. CONCLUSIONS: In pregnant women with diabetes, presence of nephropathy and/or retinopathy appear to further increase the risks of maternal complications.
引用
- Relph S, Patel T, Delaney L, et al. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis. PLoS Med. 2021. PMID: 34807920. doi:10.1371/journal.pmed.1003856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。